See original article:
In the Editorial titled, “Eligibility for Lipid-Lowering Drug Therapy in Primary Prevention,” (Circulation. 2002;105:136–139), written by Drs Antonio M. Gotto and Lewis H. Kuller, Dr Gotto indicated in the published Acknowledgment that he had received support from Merck & Co, Inc, for his contribution to the Editorial. In response to a question about this financial disclosure, the Editor wishes to clarify it for Dr Gotto.
Dr Gotto was indicating that he receives an honorarium from Merck & Co, Inc, in support of his research, writing, lecturing, and scholarly activities. He received no direct financial support for writing the Editorial in Circulation.